MEETING, Pa., July 26,
2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help protect people from infectious diseases and treat
people with cancer and HPV-associated diseases, announced today
that second quarter 2022 financial results will be released after
the market close on August 9, 2022.
Following the release, INOVIO will host a live conference call and
webcast at 4:30 p.m. EDT to discuss
financial results and provide a general business update.
A live and archived version of the audio presentation will be
available online at
http://ir.inovio.com/events-and-presentations/default.aspx. This is
a listen-only event but will include a live Q&A with
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to help treat and protect people from
infectious diseases, cancer, and diseases associated with HPV. Our
DNA medicines are delivered using our proprietary smart device to
produce immune responses against targeted pathogens and cancers.
For more information, visit www.inovio.com.
Investors & Media:
Gene Kim, (267) 589-9471,
Thomas Hong, (267) 440-4298,
SOURCE INOVIO Pharmaceuticals, Inc.